

protein and PEG flow rates, controlled by pumps, for 0.1 mg/ml and 1.0 mg/ml starting protein solutions. The absorbance and concentration values were obtained by UV absorption spectroscopy at 280 nm.

The seven-layer device had one tape, and dialysis membrane, layer in addition to the five-layer device.

The construction of the PDMS device, shown in Figure 2, began by spinning negative resist, nLOF2020, onto a silicon wafer, undergoing a soft bake, exposing, undergoing a post exposure bake, developing, etching with the Unaxis 770, and removing resist with a hot bath. PDMS was then poured over the wafer, with protection to easily remove the PDMS. The chip was then assembled by placing the PDMS and a dialysis membrane in a Harrick Plasma Cleaner and layering as seen in Figure 2.

Results and Conclusions:

As seen in Graphs 1 and 2, the five-layer device was able to concentrate a protein sample, sometimes by two-fold, and provide promising results. Graph 1 results were collected using UV absorption spectroscopy. The absorbances were converted to concentrations using the Beer-Lambert Law, $A = \epsilon Cl$. Graph 2 shows much fluctuation, which could be the result of human or machine error. The data was collected using a NanoVue spectrometer to minimize sample evaporation. Although there was concentration, there is no clear relation between flow rates and concentration.

While long-term adhesion of the dialysis membrane to the tape and PDMS remains an issue, preliminary tests with 0.1 mg/ml and 1.0 mg/ml lysozyme solutions indicate that concentration is occurring on a reasonable timescale for BioSAXS measurements. The use of thin tape, carved with the VersaLaser, is a very effective fast-prototyping method for testing microfluidic designs. Regardless of the larger than expected fluctuations in concentration over time and the formation of leaks at high PEG flow rates, an enrichment factor of approximately 50% was achieved at protein flow rates of 1 $\mu\text{l}/\text{min}$ into the device.

Based on these tests, a seven-layer chip was expected to provide a significantly increased protein concentration. The problem with the seven-layer device was placing tubes to allow fluid to travel to the middle tape layer without leaking. While further design refinements will be necessary to achieve an ideal 10-fold enrichment target, the existing five-layer device should serve as a good proof-of-concept test on the beamline. Also, the PDMS device had proper fluid flow, but it was difficult to correctly place the syringe in the channel, between the membrane and PDMS.

Future Work:

Future work should consist of increasing the shelf life of the device. The current device design is able to last for four to twelve hours of continuous fluid flow through the chip, and should be able to last for 36 to 40 hours of continuous fluid flow. Future device designs should have reduced leakage, by

covering the entire tape area with dialysis membrane, rather than just the channel area, and by placing epoxy around the sides of the device. To allow for more concentration, new devices can be designed to have longer channels, with a port for the x-ray. Also, the device should be tested in the synchrotron with an x-ray beam.



Acknowledgments:

I would like to thank the National Science Foundation (NSF), NNIN REU Program, and Cornell NanoScale Facility; Richard Gillilan, Soeren Nielsen, and Magda Moeller; Rob Ilic and Melanie-Claire Mallison, the CNF REU Program Coordinators; all of the CNF staff, but particularly Beth Rhoades for her help with the Versalaser and PDMS; and CNF user Stephen Jones.

CHESS is supported by the NSF and NIH/NIGMS award DMR-0936384. MacCHESS is supported by NIH/NCRR award RR-01646.

References:

- [1] C. Kim, et al., "Microfluidic Dialysis Device Fabrication for Protein Solution Enrichment and Its Enrichment Enhancement by Plasma Surface Treatment of a Membrane," Journal of the Korean Physical Society, September 2007.



Graph 1, top: Changes in PEG flow rates, from 0.25 $\mu\text{l}/\text{min}$ to 3 $\mu\text{l}/\text{min}$, with 0.1 mg/ml protein solution.

Graph 2, bottom: Changes in PEG flow rates, from 0.25 $\mu\text{l}/\text{min}$ to 3 $\mu\text{l}/\text{min}$, with 1.0 mg/ml protein solution.